Interestingly, when we examined three lymphoma compartments—the bone marrow (BM), the LN and the spleen (SP)—with respect to potentially remaining LC by Eμ-myc transgene-specific polymerase chain reaction (PCR) in a “minimal residual disease (MRD)”-like analysis 10 days after CTX, we found most of the control lymphoma mice-derived samples still positive, while none of the probes of the Suv39h1− group produced an MRD signal (Fig. 3d). Here, MYC is linked to lymphoma.